Requires health insurance coverage for certain neurological diseases.
Impact
If enacted, this bill would significantly alter the landscape of health insurance offerings in New Jersey. Current plans would be required to extend coverage to include essential treatments for PANDAS and PANS, thus improving access to necessary medical intervention for affected children. By making these treatments a mandated component of health insurance contracts, the bill will aim to promote early diagnosis and treatment, which could lead to better health outcomes for affected children. The requirement for comprehensive coverage may also set a precedent for future legislation related to other similar health conditions.
Summary
Assembly Bill A5325 proposes to mandate health insurance coverage for the diagnosis and treatment of Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). The bill aims to ensure that expenses related to these conditions, including prescribed medications, behavioral therapies, immunomodulating treatments, plasma exchange, and intravenous immunoglobulin therapy, are covered by health insurance plans available in New Jersey. This legislation reflects a growing recognition of the importance of addressing these specific neurological conditions in children and aims to alleviate the financial burden on families affected by these disorders.
Contention
Discussions surrounding A5325 may focus on concerns from various stakeholders regarding the implications of mandatory coverage on health insurance premiums. Opponents of such mandates often argue that they could lead to increased costs for insurance providers, which might ultimately be passed on to consumers in the form of higher premiums. Supporters, however, emphasize the necessity of ensuring that families have access to potentially life-altering treatments without incurring significant out-of-pocket expenses. Additionally, there may be deliberations on capturing and measuring the effectiveness of treatments included under this policy as a means of ensuring that coverage stays relevant and effective.
Insurance: insurers; coverage for certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406pp.
Removes the sunset provision of all statutory law requiring coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome.
Extends coverage for treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome by removing the sunset date of December 31, 2025, and mandating such coverage.
Human services: medical services; coverage for the prophylaxis, diagnosis, and treatment of certain pediatric autoimmune neuropsychiatric disorders; require. Amends 1939 PA 280 (MCL 400.1 - 400.119b) by adding sec. 109v.